GH and IGF1 in cancer therapy resistance

被引：15

作者：

Basu, Reetobrata ^{[1
]}

Kopchick, John J. ^{[1
,2
,3
]}

机构：

[1] Edison Biotechnol Inst, Athens, OH 45701 USA

[2] Ohio Univ, Mol & Cellular Biol Program, Athens, OH USA

[3] Ohio Univ, Heritage Coll Osteopath Med, Athens, OH USA

来源：

关键词：

growth hormone (GH); insulin-like growth factor 1 (IGF1); cancer; therapy resistance; radioresistance; chemoresistance; GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; GANITUMAB AMG 479; METASTATIC PANCREATIC-CANCER; PLACEBO-CONTROLLED PHASE-2; DNA-DAMAGING AGENTS; BREAST-CANCER; DOUBLE-BLIND; ENHANCES RADIOSENSITIVITY; INSULIN SENSITIVITY;

D O I：

10.1530/ERC-22-0414

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite landmark advances in cancer treatments over the last 20 years, cancer remains the second highest cause of death worldwide, much ascribed to intrinsic and acquired resistance to the available therapeutic options. In this review, we address this impending issue, by focusing the spotlight on the rapidly emerging role of growth hormone action mediated by two intimately related tumoral growth factors - growth hormone (GH) and insulin-like growth factor 1 (IGF1). Here, we not only catalog the scientific evidences relating specifically to cancer therapy resistance inflicted by GH and IGF1 but also discuss the pitfalls, merits, outstanding questions and the future need of exploiting GH-IGF1 inhibition to tackle cancer treatment successfully.

引用

页数：19

共 177 条

[1] Targeted cancer therapies [J].

Aggarwal, Saurabh .

NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (06) :427-428

[2] Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade [J].

Ajona, Daniel ;

Ortiz-Espinosa, Sergio ;

Lozano, Teresa ;

Exposito, Francisco ;

Calvo, Alfonso ;

Valencia, Karmele ;

Redrado, Miriam ;

Remirez, Ana ;

Lecanda, Fernando ;

Alignani, Diego ;

Lasarte, Juan J. ;

Macaya, Irati ;

Senent, Yaiza ;

Bertolo, Cristina ;

Sainz, Cristina ;

Gil-Bazo, Ignacio ;

Eguren-Santamaria, Inaki ;

Lopez-Picazo, Jose M. ;

Gonzalez, Alvaro ;

Perez-Gracia, Jose L. ;

de Andrea, Carlos E. ;

Vicent, Silvestre ;

Sanmamed, Miguel F. ;

Montuenga, Luis M. ;

Pio, Ruben .

NATURE CANCER, 2020, 1 (01) :75-+

[3] IGF-1R associates with adverse outcomes after radical radiotherapy for prostate cancer [J].

Aleksic, Tamara ;

Verrill, Clare ;

Bryant, Richard J. ;

Han, Cheng ;

Worrall, Andrew Ross ;

Brureau, Laurent ;

Larre, Stephane ;

Higgins, Geoff S. ;

Fazal, Fahad ;

Sabbagh, Ahmad ;

Haider, Syed ;

Buffa, Francesca M. ;

Cole, David ;

Macaulay, Valentine M. .

BRITISH JOURNAL OF CANCER, 2017, 117 (11) :1600-1606

[4] Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors [J].

Amin, Oreekha ;

Beauchamp, Marie-Claude ;

Abou Nader, Paul ;

Laskov, Ido ;

Iqbal, Sanaa ;

Philip, Charles-Andre ;

Yasmeen, Amber ;

Gotlieb, Walter H. .

BMC CANCER, 2015, 15

[5] IGF2/IGF1R Signaling as a Therapeutic Target in MYB-Positive Adenoid Cystic Carcinomas and Other Fusion Gene-Driven Tumors [J].

Andersson, Mattias K. ;

Aman, Pierre ;

Stenman, Goran .

CELLS, 2019, 8 (08)

[6] Silencing growth hormone receptor inhibits estrogen receptor negative breast cancer through ATP-binding cassette sub-family G member 2 [J].

Arumugam, Arunkumar ;

Subramani, Ramadevi ;

Nandy, Sushmita Bose ;

Terreros, Daniel ;

Dwivedi, Alok Kumar ;

Saltzstein, Edward ;

Lakshmanaswamy, Rajkumar .

EXPERIMENTAL AND MOLECULAR MEDICINE, 2019, 51 (1) :1-13

[7] Growth hormone and its disorders [J].

Ayuk, J ;

Sheppard, MC .

POSTGRADUATE MEDICAL JOURNAL, 2006, 82 (963) :24-30

[8] Growth hormone promotes lymphangiogenesis [J].

Banziger-Tobler, Nadja Erika ;

Halin, Cornelia ;

Kajiya, Kentaro ;

Detmar, Michael .

AMERICAN JOURNAL OF PATHOLOGY, 2008, 173 (02) :586-597

[9] The decline and fall of the IGF-I receptor [J].

Baserga, Renato .

JOURNAL OF CELLULAR PHYSIOLOGY, 2013, 228 (04) :675-679

[10] Growth hormone receptor antagonism downregulates ATP-binding cassette transporters contributing to improved drug efficacy against melanoma and hepatocarcinoma in vivo [J].

Basu, Reetobrata ;

Qian, Yanrong ;

Mathes, Samuel ;

Terry, Joseph ;

Arnett, Nathan ;

Riddell, Trent ;

Stevens, Austin ;

Funk, Kevin ;

Bell, Stephen ;

Bokal, Zac ;

Batten, Courtney ;

Smith, Cole ;

Mendez-Gibson, Isaac ;

Duran-Ortiz, Silvana ;

Lach, Grace ;

Mora-Criollo, Patricia Alexandra ;

Kulkarni, Prateek ;

Davis, Emily ;

Teaford, Elizabeth ;

Berryman, Darlene E. ;

List, Edward O. ;

Neggers, Sebastian ;

Kopchick, John J. .

FRONTIERS IN ONCOLOGY, 2022, 12

← 1 2 3 4 5 6 7 8 9 10 →